Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Retatrutide is a novel triple receptor agonist peptide that targets the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R)
Clinical trials have shown that Wegovy Pill users can lose on average 14% or up to 20% of their initial body weight
Patents for Wegovy and Zepbound should expire in 2031-2032, which could see cheaper generics being launched
It's not a pharmaceutical GLP-1 drug
Your concentration becomes 7.5 mg/mL instead of 10 mg/mL
Ozempic is FDA-approved for diabetes, Wegovy is FDA-approved for weight loss, and Rybelsus is an oral tablet FDA-approved for type 2 diabetes
US$ 25.83
US$ 23.09
US$ 28.51
